2020 American Transplant Congress
Trust and Transparency in Artificial Intelligence-Aided Immunosuppression Decisions
Information and Decision Sciences, University of Minnesota, Minneapolis, MN
*Purpose: In transplant, there is significant interest in using Artificial Intelligence (including machine learning or predictive models) Clinical Decision Support Systems(AI CDSS). Properly designing and…2020 American Transplant Congress
Effect of Glecaprevir/Pibrentasvir on Weight-Adjusted Tacrolimus Trough/Dose Ratios in Heart and Kidney Recipients
*Purpose: An innovative strategy to meet the demands of patients requiring heart or kidney transplantation is the acceptance of hepatitis C viremic organs. Direct acting…2020 American Transplant Congress
Assessment of Time to Therapeutic Tacrolimus Levels Following Renal Transplantation in a Non-Weight-Based Dosing Model
*Purpose: The optimal initial dose for tacrolimus (TAC) after renal transplant (RT) remains controversial with limited evidence comparing weight-based and conservative strategies. Recent literature suggests…2020 American Transplant Congress
Early Calculation of the Tacrolimus Concentration-to-Dose Ratio Does Not Predict Outcomes after Renal Transplantation
Department of Internal Medicine D, University Hospital Münster, Münster, Germany
*Purpose: There is emerging interest in the concentration-to-dose (C/D) ratio of tacrolimus (Tac) as it is linked to outcomes after renal transplantation (RTx). Recently, we…2020 American Transplant Congress
Clinical Implications of Tacrolimus Time in Therapeutic Range in Urban Renal Transplant Recipients Under an Early Corticosteroid Withdrawal Protocol
University of Illinois at Chicago, Chicago, IL
*Purpose: Tacrolimus displays wide inter- and intra-patient variability, necessitating therapeutic drug monitoring. Assessing the duration of time in therapeutic range (TTR) is an additional tool…2020 American Transplant Congress
Specific Gut Microbiota Community Suppresses Acute Rejection by Reducing Natural Killer Cell Population
*Purpose: The gut microbiota community was reported to be altered by high-dose FK506 treatment, while fecal microbiota transplantation with such microbiota plus low-dose FK506 could…2020 American Transplant Congress
Dosing and Outcomes of Conversion to Extended-Release Tacrolimus in Heart and Lung Transplant Recipients
*Purpose: Extended release tacrolimus (LCP-Tac) is a novel once daily formulation with improved pharmacokinetic parameters compared to immediate release tacrolimus (IR-Tac). LCP-Tac use in renal…2020 American Transplant Congress
Protective Effect of Fucoidan Against Tacrolimus-Induced Nephrotoxicity in LLC-PK1 Cells
Surgery, University of Ulsan, Gangneung Asan Hospital, Gangneung, Korea, Republic of
*Purpose: Tacrolimus (FK506) is an immunosuppressant agent that is frequently used to prevent rejection of solid organs upon transplant. However, nephrotoxicity due to apoptosis and…2020 American Transplant Congress
The Effects of Rivaroxaban and Apixaban on Tacrolimus Pharmacokinetics
*Purpose: To clarify the pharmacokinetic impact of rivaroxaban (RIVA) and apixaban (APIX) on tacrolimus (TAC) concentrations.*Methods: Solid organ transplant recipients 18-years or older who were…2020 American Transplant Congress
Envarsus XR Use Can Benefit Serum Creatinine Levels in Vascularized Composite Allotransplantation Patients
*Purpose: Vascularized composite allotransplantation (VCA) is a life-enhancing (as opposed to life-saving) procedure. Therefore, minimizing adverse outcomes associated with chronic immunosuppression is vital to determining…
American Transplant Congress abstracts